Please assess the completion status of the following clinical trial:

Trial Title: China-Administration of Nicorandil Group（CHANGE）

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute ST-T elevation MI patients (\<12h)~2. undergoing emergency PCI；~3. Subject has read and signed a written, informed consent form.~Exclusion Criteria:~1. SBP\<80mmHg；~2. LM stenosis~3. Aortic dissection；~4. AMI (\<6 month)~5. PCI或CABG (\<6 month)~6. Already under the treatment of Nicorandil；~7. Contraindicated or intolerable to Nicorandil~8. severe adverse effects to CMR or MRI；~9. Currently (or within one month) participating in another new drug trial.；~10. Pregnant or lactation period；~11. Severe somatic disease preventing the participant from completing the trial, or based on the discretion of the investigators, the patient is incapable of participating; Individuals with abnormal laboratory test results and/or clinical manifestations rendering them unsuitable to participate as judged by the investigators;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
- Placebo arm (Type: PLACEBO_COMPARATOR): Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.

Based on this trial design, predict the completion outcome and termination type (if applicable).